Sun said to be discussing $2.3B deal for Intas: DealStreetAsia

Sun Pharmaceutical is reported to be in negotiations to buy Indian rival Intas Pharmaceuticals for as much as $2.3 billion, talks that Intas says are not happening. In an exclusive based on unnamed sources, DealStreetAsia says the two companies are discussing a cash and stock deal that would give Sun entry into biosimilars. Intas is hoping to be the first Indian drugmaker to sell biosimilars in the U.S. with its version of Amgen's ($AMGN) Neulasta. More from FiercePharmaAsia